

**TABLE 2.** Targets of novel complement inhibitors in ongoing clinical trials

Targets	Disease studied
C5	PNH, AMD, TMA, Vasculitis, HUS, Acute GI-GVHD, APS
C3/C3b	AMD, PNH, TMA
APC C3 convertase	PNH, TMA
APC and CP convertase	Transplantation, TMA
factor B	AMD, TMA
factor D	AMD, PNH
C1	HAE, Transplantation, CAD
C4 cleavage	TMA
MASP-2	TMA
MASP-3	PNH, TMA
Properdin	AMD, PNH

*APC: alternative pathway of complement; TMA: thrombotic microangiopathy; MASP: MBL-associated serine proteases; AMD: age-related macular degeneration; GI-GVHD: gastrointestinal track graft-versus-host disease; APS: antiphospholipid syndrome; PNH: Paroxysmal nocturnal hemoglobinuria; TMA: thrombotic microangiopathy; HAE: hereditary angioedema; CAD: cold-agglutinin disease*